NCT01328587View on ClinicalTrials.gov

Eltrombopag for Moderate Aplastic Anemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 1, 2011

Primary Completion Date

March 30, 2018

Study Completion Date

June 30, 2025

Conditions
Moderate Aplastic AnemiaUnilineage Bone Marrow Failure Disorders
Interventions
DRUG

Eltrombopag

Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH